Bioimpacts. 2016;6(4): 225-248. doi: 10.15171/bi.2016.30
PMID: 28265539        PMCID: PMC5326671

Review

Blood-brain barrier transport machineries and targeted therapy of brain diseases


Cited by CrossRef: 25


1- Salatin S, Barar J, Barzegar-Jalali M, Adibkia K, Jelvehgari M. Thermosensitive in situ nanocomposite of rivastigmine hydrogen tartrate as an intranasal delivery system: Development, characterization, ex vivo permeation and cellular studies. Colloids and Surfaces B: Biointerfaces. 2017;159:629 [Crossref]
2- Suchorska B, Albert N, Bauer E, Tonn J, Galldiks N. The role of amino-acid PET in the light of the new WHO classification 2016 for brain tumors. Q J Nucl Med Mol Imaging. 2018;62(3) [Crossref]
3- Hu L, Wang Y, Zhang Y, Yang N, Han H, Shen Y, Cui D, Guo S. Angiopep-2 modified PEGylated 2-methoxyestradiol micelles to treat the PC12 cells with oxygen-glucose deprivation/reoxygenation. Colloids and Surfaces B: Biointerfaces. 2018;171:638 [Crossref]
4- Kim J, Ahn S, Kim Y. Nanotherapeutics engineered to cross the blood-brain barrier for advanced drug delivery to the central nervous system. Journal of Industrial and Engineering Chemistry. 2019;73:8 [Crossref]
5- Jojo G, Kuppusamy G. Scope of new formulation approaches in the repurposing of pioglitazone for the management of Alzheimer’s disease. J Clin Pharm Ther. 2019; [Crossref]
6- Qosa H, Volpe D. The development of biological therapies for neurological diseases: moving on from previous failures. Expert Opinion on Drug Discovery. 2018;13(4):283 [Crossref]
7- Uwamori H, Ono Y, Yamashita T, Arai K, Sudo R. Comparison of organ-specific endothelial cells in terms of microvascular formation and endothelial barrier functions. Microvascular Research. 2019;122:60 [Crossref]
8- Esposito C, Nuzzo S, Catuogno S, Romano S, de Nigris F, de Franciscis V. STAT3 Gene Silencing by Aptamer-siRNA Chimera as Selective Therapeutic for Glioblastoma. Molecular Therapy - Nucleic Acids. 2018;10:398 [Crossref]
9- Moura R, Martins C, Pinto S, Sousa F, Sarmento B. Blood-brain barrier receptors and transporters: an insight on their function and how to exploit them through nanotechnology. Expert Opinion on Drug Delivery. 2019;16(3):271 [Crossref]
10- Li M, Shi K, Tang X, Wei J, Cun X, Chen X, Yu Q, Zhang Z, He Q. pH-sensitive folic acid and dNP2 peptide dual-modified liposome for enhanced targeted chemotherapy of glioma. European Journal of Pharmaceutical Sciences. 2018;124:240 [Crossref]
11- de Franciscis V. Challenging cancer targets for aptamer delivery. Biochimie. 2018;145:45 [Crossref]
12- Gallo M, Defaus S, Andreu D. 1988–2018: Thirty years of drug smuggling at the nano scale. Challenges and opportunities of cell-penetrating peptides in biomedical research. Archives of Biochemistry and Biophysics. 2019;661:74 [Crossref]
13- Pulgar V. Transcytosis to Cross the Blood Brain Barrier, New Advancements and Challenges. Front Neurosci. 2019;12 [Crossref]
14- Moscariello P, Ng D, Jansen M, Weil T, Luhmann H, Hedrich J. Brain Delivery of Multifunctional Dendrimer Protein Bioconjugates. Adv Sci. 2018;5(5):1700897 [Crossref]
15- Kumar M, Sharma G, Kumar R, Singh B, Katare O, Raza K. Lysine-Based C60-Fullerene Nanoconjugates for Monomethyl Fumarate Delivery: A Novel Nanomedicine for Brain Cancer Cells. ACS Biomater Sci Eng. 2018;4(6):2134 [Crossref]
16- Majzúnová M, Pakanová Z, Kvasnička P, Bališ P, Čačányiová S, Dovinová I. Age-dependent redox status in the brain stem of NO-deficient hypertensive rats. J Biomed Sci. 2017;24(1) [Crossref]
17- Zubkov E, Zorkina Y, Orshanskaya E, Khlebnikova N, Krupina N, Chekhonin V. Changes in Gene Expression Profiles in Adult Rat Brain Structures after Neonatal Action of Dipeptidyl Peptidase-IV Inhibitors. Neuropsychobiology. 2017;76(2):89 [Crossref]
18- Khan A, Yang X, Fu M, Zhai G. Recent progress of drug nanoformulations targeting to brain. Journal of Controlled Release. 2018;291:37 [Crossref]
19- Kang J, Cho J, Ko Y. Investigation on the effect of nanoparticle size on the blood–brain tumour barrier permeability by in situ perfusion via internal carotid artery in mice. Journal of Drug Targeting. 2019;27(1):103 [Crossref]
20- Safary A, Akbarzadeh Khiavi M, Mousavi R, Barar J, Rafi M. Enzyme replacement therapies: what is the best option?. Bioimpacts. 2018;8(3):153 [Crossref]
21- Hajal C, Campisi M, Mattu C, Chiono V, Kamm R. In vitro models of molecular and nano-particle transport across the blood-brain barrier. Biomicrofluidics. 2018;12(4):042213 [Crossref]
22- Teleanu D, Negut I, Grumezescu V, Grumezescu A, Teleanu R. Nanomaterials for Drug Delivery to the Central Nervous System. Nanomaterials. 2019;9(3):371 [Crossref]
23- Zamanlu M, Farhoudi M, Eskandani M, Mahmoudi J, Barar J, Rafi M, Omidi Y. Recent advances in targeted delivery of tissue plasminogen activator for enhanced thrombolysis in ischaemic stroke. Journal of Drug Targeting. 2018;26(2):95 [Crossref]
24- Wang F, Cao Y, Ma L, Pei H, Rausch W, Li H. Dysfunction of Cerebrovascular Endothelial Cells: Prelude to Vascular Dementia. Front Aging Neurosci. 2018;10 [Crossref]
25- Teleanu D, Chircov C, Grumezescu A, Volceanov A, Teleanu R. Blood-Brain Delivery Methods Using Nanotechnology. Pharmaceutics. 2018;10(4):269 [Crossref]

BioImpacts, as a peer-reviewed international journal, publishes all types of papers on bench-to-bedside translational aspects of pharmaceutical and biomedical sciences. As a "Publish Free" and "Access Free" journal, BioImpacts follows a constructive peer-review process with free editing service to benefit the scientific community worldwide.